Pub Date : 2021-05-25eCollection Date: 2021-01-01DOI: 10.3233/BLC-201510
Erik Veskimae, Selvarani Subbarayan, Riccardo Campi, Domitille Carron, Muhammad Imran Omar, Cathy Yuan, Konstantinos Dimitropoulos, Mieke Van Hemelrijck, Richard T Bryan, James N'Dow, Marek Babjuk, J Alfred Witjes, Richard Sylvester, Steven MacLennan
Background: Heterogenous outcome reporting in non-muscle-invasive bladder cancer (NMIBC) effectiveness trials of adjuvant treatment after transurethral resection (TURBT) has been noted in systematic reviews (SRs). This hinders comparing results across trials, combining them in meta-analyses, and evidence-based decision-making for patients and clinicians.
Objective: We aimed to systematically review the extent of reporting and definition heterogeneity.
Methods: We included randomized controlled trials (RCTs) identified from SRs comparing adjuvant treatments after TURBT or TURBT alone in patients with NMIBC (with or without carcinoma in situ) published between 2000-2020. Abstracts and full texts were screened independently by two reviewers. Data were extracted by one reviewer and checked by another.
Results: We screened 807 abstracts; from 15 SRs, 57 RCTs were included. Verbatim outcome names were coded to standard outcome names and organised using the Williamson and Clarke taxonomy. Recurrence (98%), progression (74%), treatment response (in CIS studies) (40%), and adverse events (77%) were frequently reported across studies. However, overall (33%) and cancer-specific (33%) survival, treatment completion (17%) and treatment change (37%) were less often reported. Quality of Life (3%) and economic outcomes (2%) were rarely reported. Heterogeneity was evident throughout, particularly in the definitions of progression and recurrence, and how CIS patients were handled in the analysis of studies with predominantly papillary patients, highlighting further issues with the definition of recurrence and progression vs treatment response for CIS patients. Data reporting was also inconsistent, with some trials reporting event rates at various time-points and others reporting time-to-event with or without Hazard Ratios. Adverse events were inconsistently reported. QoL data was absent in most trials.
Conclusions: Heterogenous outcome reporting is evident in NMIBC effectiveness trials. This has profound implications for meta-analyses, SRs and evidence-based treatment decisions. A core outcome set is required to reduce heterogeneity.
Patient summary: This systematic review found inconsistencies in outcome definitions and reporting, pointing out the urgent need for a core outcome set to help improve evidence-based treatment decisions.
{"title":"A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection.","authors":"Erik Veskimae, Selvarani Subbarayan, Riccardo Campi, Domitille Carron, Muhammad Imran Omar, Cathy Yuan, Konstantinos Dimitropoulos, Mieke Van Hemelrijck, Richard T Bryan, James N'Dow, Marek Babjuk, J Alfred Witjes, Richard Sylvester, Steven MacLennan","doi":"10.3233/BLC-201510","DOIUrl":"10.3233/BLC-201510","url":null,"abstract":"<p><strong>Background: </strong>Heterogenous outcome reporting in non-muscle-invasive bladder cancer (NMIBC) effectiveness trials of adjuvant treatment after transurethral resection (TURBT) has been noted in systematic reviews (SRs). This hinders comparing results across trials, combining them in meta-analyses, and evidence-based decision-making for patients and clinicians.</p><p><strong>Objective: </strong>We aimed to systematically review the extent of reporting and definition heterogeneity.</p><p><strong>Methods: </strong>We included randomized controlled trials (RCTs) identified from SRs comparing adjuvant treatments after TURBT or TURBT alone in patients with NMIBC (with or without carcinoma <i>in situ</i>) published between 2000-2020. Abstracts and full texts were screened independently by two reviewers. Data were extracted by one reviewer and checked by another.</p><p><strong>Results: </strong>We screened 807 abstracts; from 15 SRs, 57 RCTs were included. Verbatim outcome names were coded to standard outcome names and organised using the Williamson and Clarke taxonomy. Recurrence (98%), progression (74%), treatment response (in CIS studies) (40%), and adverse events (77%) were frequently reported across studies. However, overall (33%) and cancer-specific (33%) survival, treatment completion (17%) and treatment change (37%) were less often reported. Quality of Life (3%) and economic outcomes (2%) were rarely reported. Heterogeneity was evident throughout, particularly in the definitions of progression and recurrence, and how CIS patients were handled in the analysis of studies with predominantly papillary patients, highlighting further issues with the definition of recurrence and progression vs treatment response for CIS patients. Data reporting was also inconsistent, with some trials reporting event rates at various time-points and others reporting time-to-event with or without Hazard Ratios. Adverse events were inconsistently reported. QoL data was absent in most trials.</p><p><strong>Conclusions: </strong>Heterogenous outcome reporting is evident in NMIBC effectiveness trials. This has profound implications for meta-analyses, SRs and evidence-based treatment decisions. A core outcome set is required to reduce heterogeneity.</p><p><strong>Patient summary: </strong>This systematic review found inconsistencies in outcome definitions and reporting, pointing out the urgent need for a core outcome set to help improve evidence-based treatment decisions.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 2","pages":"221-241"},"PeriodicalIF":1.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
[This corrects the article DOI: 10.3233/BLC-200332.].
[此处更正了文章 DOI:10.3233/BLC-200332]。
{"title":"Erratum: Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx.","authors":"","doi":"10.3233/BLC-219501","DOIUrl":"10.3233/BLC-219501","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200332.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"111-112"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/45/blc-7-blc219501.PMC8080894.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38908688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-19eCollection Date: 2021-01-01DOI: 10.3233/BLC-219602
Mark S Soloway, Neil A Abrahams
[This corrects the article DOI: 10.3233/BLC-200004.].
[此处更正了文章 DOI:10.3233/BLC-200004]。
{"title":"Erratum: Challenging Cases in Urothelial Cancer.","authors":"Mark S Soloway, Neil A Abrahams","doi":"10.3233/BLC-219602","DOIUrl":"https://doi.org/10.3233/BLC-219602","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200004.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"115"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-19eCollection Date: 2021-01-01DOI: 10.3233/BLC-200387
Lauren E Powell, Theodore I Cisu, Adam P Klausner
Background: Understanding of health-related materials, termed health literacy, affects decision makings and outcomes in the treatment of bladder cancer. The National Institutes of Health recommend writing education materials at a sixth-seventh grade reading level. The goal of this study is to assess readability of bladder cancer materials available online.
Objective: The goal of this study is to characterize available information about bladder cancer online and evaluate readability.
Methods: Materials on bladder cancer were collected from the American Urological Association's Urology Care Foundation (AUA-UCF) and compared to top 50 websites by search engine results. Resources were analyzed using four different validated readability assessment scales. The mean and standard deviation of the materials was calculated, and a two-tailed t test for used to assess for significance between the two sets of patient education materials.
Results: The average readability of AUA materials was 8.5 (8th-9th grade reading level). For the top 50 websites, average readability was 11.7 (11-12th grade reading level). A two-tailed t test between the AUA and top 50 websites demonstrated statistical significance between the readability of the two sets of resources (P = 0.0001), with the top search engine results being several grade levels higher than the recommended 6-7th grade reading level.
Conclusions: Most health information provided by the AUA on bladder cancer is written at a reading ability that aligns with most US adults, with top websites for search engine results exceeding the average reading level by several grade levels. By focusing on health literacy, urologists may contribute lowering barriers to health literacy, improving health care expenditure and perioperative complications.
{"title":"Bladder Cancer Health Literacy: Assessing Readability of Online Patient Education Materials.","authors":"Lauren E Powell, Theodore I Cisu, Adam P Klausner","doi":"10.3233/BLC-200387","DOIUrl":"10.3233/BLC-200387","url":null,"abstract":"<p><strong>Background: </strong>Understanding of health-related materials, termed health literacy, affects decision makings and outcomes in the treatment of bladder cancer. The National Institutes of Health recommend writing education materials at a sixth-seventh grade reading level. The goal of this study is to assess readability of bladder cancer materials available online.</p><p><strong>Objective: </strong>The goal of this study is to characterize available information about bladder cancer online and evaluate readability.</p><p><strong>Methods: </strong>Materials on bladder cancer were collected from the American Urological Association's Urology Care Foundation (AUA-UCF) and compared to top 50 websites by search engine results. Resources were analyzed using four different validated readability assessment scales. The mean and standard deviation of the materials was calculated, and a two-tailed <i>t</i> test for used to assess for significance between the two sets of patient education materials.</p><p><strong>Results: </strong>The average readability of AUA materials was 8.5 (8th-9th grade reading level). For the top 50 websites, average readability was 11.7 (11-12th grade reading level). A two-tailed <i>t</i> test between the AUA and top 50 websites demonstrated statistical significance between the readability of the two sets of resources (<i>P</i> = 0.0001), with the top search engine results being several grade levels higher than the recommended 6-7th grade reading level.</p><p><strong>Conclusions: </strong>Most health information provided by the AUA on bladder cancer is written at a reading ability that aligns with most US adults, with top websites for search engine results exceeding the average reading level by several grade levels. By focusing on health literacy, urologists may contribute lowering barriers to health literacy, improving health care expenditure and perioperative complications.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"91-98"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-19eCollection Date: 2021-01-01DOI: 10.3233/BLC-219603
Mark S Soloway
[This corrects the article DOI: 10.3233/BLC-200007.].
[此处更正了文章 DOI:10.3233/BLC-200007.]。
{"title":"Erratum: Challenging Cases in Urothelial Cancer: Case 17.","authors":"Mark S Soloway","doi":"10.3233/BLC-219603","DOIUrl":"https://doi.org/10.3233/BLC-219603","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200007.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"117"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-19eCollection Date: 2021-01-01DOI: 10.3233/BLC-200015
Mark S Soloway, Neil A Abrahams
{"title":"Challenging Cases in Urothelial Cancer: Case 19.","authors":"Mark S Soloway, Neil A Abrahams","doi":"10.3233/BLC-200015","DOIUrl":"10.3233/BLC-200015","url":null,"abstract":"","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"1 1","pages":"99-102"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69809167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-19eCollection Date: 2021-01-01DOI: 10.3233/BLC-219604
Mark S Soloway
[This corrects the article DOI: 10.3233/BLC-200009.].
[此处更正了文章 DOI:10.3233/BLC-200009]。
{"title":"Erratum: Challenging Cases in Urothelial Cancer: Case 18.","authors":"Mark S Soloway","doi":"10.3233/BLC-219604","DOIUrl":"https://doi.org/10.3233/BLC-219604","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200009.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"119"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}